Long Term Outcomes of First Line Tyrosine Kinase Inhibitors for Chronic Phase Chronic Myeloid Leukemia: A Mixed-Treatment Comparison

被引：0
|
作者：
Firwana, Belal [1 ]
Sonbol, Mohamad Bassam [2 ]
Diab, Maria [3 ]
Hasan, Rim [1 ]
Yousef, Ibraheem [1 ]
Garipalli, Archana [1 ]
Raza, Shahzad [4 ]
Al-Kali, Aref [5 ]
Doll, Donald [4 ]
机构：
[1] Univ Missouri, Columbia, MO USA
[2] Georgia Regents Univ, Augusta, GA USA
[3] Wayne State Univ, Detroit, MI USA
[4] Univ Missouri, Columbia, MO USA
[5] Mayo Clin, Rochester, MN USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Outcomes of Chronic Phase Chronic Myeloid Leukemia (CP-CML) after Sequential Treatment with Tyrosine Kinase Inhibitors (TKI)
    Kong, Jee Hyun
    Winton, Elliott F.
    Heffner, Leonard
    Gaddh, Manila
    Hill, Brittany
    Arellano, Martha L.
    El-Rassi, Fuad
    Kim, Audrey
    Kota, Vamsi
    BLOOD, 2017, 130
  • [22] Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-Line Tyrosine Kinase Inhibitors
    Sasaki, Koji
    Jabbour, Elias
    Issa, Ghayas C.
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Wierda, William G.
    Yilmaz, Musa
    DiNardo, Courtney D.
    Skinner, Jeffrey
    Khouri, Maria
    Pemmaraju, Naveen
    Nasnas, Patrice
    Pierce, Sherry A.
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    BLOOD, 2020, 136
  • [23] Front-line use of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: Practice considerations
    Reff, Michael J.
    Shillingburg, Alexandra
    Shah, Bhavesh
    Elder, Christopher
    Prescott, Hillary
    Kennerly-Shah, Julie
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (01) : 156 - 174
  • [24] Outcomes of Chronic Phase Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitors Dose-Reductions
    Kong, Jee Hyun
    Khoury, Hanna Jean
    Winton, Elliott F.
    Heffner, Leonard T.
    Gaddh, Manila
    Arellano, Martha
    El-Rassi, Fuad
    Kim, Audrey S.
    Jillella, Anand
    Bodo, Imre
    Kota, Vamsi
    BLOOD, 2016, 128 (22)
  • [25] Long-Term Results of Tyrosine Kinase Inhibitors Discontinuation in Patients With Chronic Myeloid Leukemia
    Petrova, Anna
    Chelysheva, Ekaterina
    Shukhov, Oleg
    Julhakyan, Hunan
    Bykova, Anastasiya
    Nemchenko, Irina
    Martynkevich, Irina
    Turkina, Anna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S291 - S291
  • [26] Long-Term Outcomes after Allogeneic Stem Cell Transplantation Versus New Generation Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia
    Lomaia, Elza
    Kulemina, Olga
    Vlasova, Julia
    Matvienko, Julia
    Yakovleva, Julia
    Ovsyannikova, Ekaterina
    Badaev, Renat
    Sbityakova, Evgeniya
    Alexeeva, Yulia
    Morozova, Elena
    BLOOD, 2024, 144 : 6607 - 6608
  • [27] When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
    Pierre Laneuville
    Current Treatment Options in Oncology, 2018, 19
  • [28] When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
    Laneuville, Pierre
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (03)
  • [29] ASSESSMENT OF EFFICACY OF TYROSINE KINASE INHIBITORS IN TREATMENT OF CHRONIC MYELOID LEUKEMIA
    Yadrikhinskaya, V. N.
    Mulina, I. I.
    Sannikova, A. N.
    Palshina, A. M.
    Sleptsova, S. S.
    Aleksandrova, T. N.
    YAKUT MEDICAL JOURNAL, 2016, (04): : 30 - 33
  • [30] Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
    Baccarani, Michele
    Castagnetti, Fausto
    Gugliotta, Gabriele
    Palandri, Francesca
    Rosti, Gianantonio
    EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (03) : 397 - 406
12345